TY - JOUR
T1 - Targeting Glioblastoma Stem Cells
T2 - A40s Aptamer-NIR-Dye Conjugate for Glioblastoma Visualization and Treatment
AU - Affinito, Alessandra
AU - Ingenito, Francesco
AU - Verde, Sara
AU - Musella, Emanuele
AU - Pattanayak, Birlipta
AU - Fiore, Danilo
AU - Quintavalle, Cristina
AU - Fraticelli, Aurelia
AU - Mascolo, Martina
AU - Petrillo, Gianluca
AU - Pignataro, Claudia
AU - De Luca, Giada
AU - Mezzanotte, Laura
AU - Condorelli, Gerolama
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/5/27
Y1 - 2025/5/27
N2 - Glioblastoma (GBM) is the most aggressive and challenging brain cancer, in terms of diagnosis and therapy. The highly infiltrative glioblastoma stem cells (GSCs) are difficult to visualize and surgically remove with the current diagnostic tools, which often lead to misdiagnosis and false-positive results. In this study, we focused on a groundbreaking tool for specifically visualizing and removing GSCs. We exploited the specific binding of A40s aptamer to EphA2 for the selective delivery of Near-Infrared Dyes (NIR-Dyes), like IR700DX and ICG, both in vitro and in vivo. The A40s aptamer, engineered through the NIR-Dye conjugation, did not affect aptamer binding ability; indeed, A40s-NIR-Dye conjugates bound GLI261 stem-like cells and patient-derived GSCs in vitro; moreover, they induced cell death upon photodynamic therapy treatment (PDT). Additionally, when systemically administrated, the A40s-NIR-Dye conjugates allowed GSC visualization and accumulated in tumor mass. This allows GSCs detection and treatment. Our findings demonstrate the potential use of A40s aptamer as a targeted therapeutic approach and imaging tool in vivo for GSCs, paving the way for improved, more effective, and less invasive GBM management.
AB - Glioblastoma (GBM) is the most aggressive and challenging brain cancer, in terms of diagnosis and therapy. The highly infiltrative glioblastoma stem cells (GSCs) are difficult to visualize and surgically remove with the current diagnostic tools, which often lead to misdiagnosis and false-positive results. In this study, we focused on a groundbreaking tool for specifically visualizing and removing GSCs. We exploited the specific binding of A40s aptamer to EphA2 for the selective delivery of Near-Infrared Dyes (NIR-Dyes), like IR700DX and ICG, both in vitro and in vivo. The A40s aptamer, engineered through the NIR-Dye conjugation, did not affect aptamer binding ability; indeed, A40s-NIR-Dye conjugates bound GLI261 stem-like cells and patient-derived GSCs in vitro; moreover, they induced cell death upon photodynamic therapy treatment (PDT). Additionally, when systemically administrated, the A40s-NIR-Dye conjugates allowed GSC visualization and accumulated in tumor mass. This allows GSCs detection and treatment. Our findings demonstrate the potential use of A40s aptamer as a targeted therapeutic approach and imaging tool in vivo for GSCs, paving the way for improved, more effective, and less invasive GBM management.
UR - https://www.scopus.com/pages/publications/105009081646
U2 - 10.3390/biom15060768
DO - 10.3390/biom15060768
M3 - Article
C2 - 40563410
AN - SCOPUS:105009081646
SN - 2218-273X
VL - 15
JO - Biomolecules
JF - Biomolecules
IS - 6
M1 - 768
ER -